3 recruiting, 1 completed, 1 not yet recruiting. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Completed 1, Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Odronextamab: new trials by email Literature Review of Odronextamab trials Research Report on Odronextamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) REGN9220, Odronextamab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 36 | 2026-12-07 | 2026-10-21 |
| Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis Vonsetamig, Odronextamab - Lupus Nephritis (LN) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 90 | 2025-12-22 | 2026-10-27 |
| Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 23 | 2025-08-14 | 2026-09-16 |
| A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas Odronextamab, REGN5837 - B-cell Non-Hodgkins Lymphoma (B-NHL) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 107 | 2023-04-20 | 2026-05-19 |
| A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies cemiplimab, odronextamab - Relapsed/Refractory Aggressive B-Cell Lymphoma | Phase 1 | Completed | Regeneron Pharmaceuticals | 105 | 2016-01-11 | 2026-06-02 |
Recurrence (2) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1)
Regeneron Pharmaceuticals (4) · City of Hope Medical Center (1)
United States (4) · Spain (3) · France (2) · Germany (2) · Austria (1) · Israel (1) · Netherlands (1) · Poland (1) · South Korea (1) · Taiwan (1) · United Kingdom (1)
Alexey V Danilov (1)
2015 (1), 2023 (1), 2025 (1), P30CA033572 (1)